RJA
OPK icon

Raymond James & Associates’s Opko Health OPK Stock Holding History

Raymond James & Associates’s Portfolio OPK Stock Details OPK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$57.6K Buy
38,665
+400
+1% +$594 ﹤0.01% 3837
2024
Q2 		$47.8K Hold
38,265
– – ﹤0.01% 3796
2024
Q1 		$45.9K Sell
38,265
-700
-2% -$701 ﹤0.01% 3811
2023
Q4 		$58.8K Sell
38,965
-1,600
-4% -$2.31K ﹤0.01% 3693
2023
Q3 		$64.9K Sell
40,565
-8,781
-18% -$16K ﹤0.01% 3654
2023
Q2 		$107K Buy
49,346
+8,051
+19% +$12.6K ﹤0.01% 3616
2023
Q1 		$60.3K Sell
41,295
-2,001
-5% -$2.58K ﹤0.01% 3715
2022
Q4 		$54.1K Sell
43,296
-22,799
-34% -$35.9K ﹤0.01% 3710
2022
Q3 		$125K Hold
66,095
– – ﹤0.01% 3565
2022
Q2 		$167K Buy
66,095
+6,313
+11% +$18.4K ﹤0.01% 3567
2022
Q1 		$206K Sell
59,782
-7,200
-11% -$25.4K ﹤0.01% 3654
2021
Q4 		$322K Sell
66,982
-13,004
-16% -$52.6K ﹤0.01% 3391
2021
Q3 		$292K Buy
79,986
+4,672
+6% +$17.4K ﹤0.01% 3431
2021
Q2 		$305K Sell
75,314
-1,000
-1% -$3.92K ﹤0.01% 3424
2021
Q1 		$327K Buy
76,314
+1,560
+2% +$7.45K ﹤0.01% 3297
2020
Q4 		$295K Sell
74,754
-10,360
-12% -$43.3K ﹤0.01% 3130
2020
Q3 		$314K Sell
85,114
-39,100
-31% -$165K ﹤0.01% 2930
2020
Q2 		$424K Sell
124,214
-30,313
-20% -$67.9K ﹤0.01% 2700
2020
Q1 		$207K Sell
154,527
-2,748
-2% -$4.31K ﹤0.01% 3023
2019
Q4 		$231K Sell
157,275
-6,675
-4% -$11.2K ﹤0.01% 3256
2019
Q3 		$343K Sell
163,950
-24,100
-13% -$49.2K ﹤0.01% 2927
2019
Q2 		$459K Buy
188,050
+5,602
+3% +$12.2K ﹤0.01% 2741
2019
Q1 		$476K Sell
182,448
-30,742
-14% -$93.1K ﹤0.01% 2686
2018
Q4 		$642K Sell
213,190
-41,200
-16% -$140K ﹤0.01% 2376
2018
Q3 		$880K Sell
254,390
-13,031
-5% -$69.2K ﹤0.01% 2330
2018
Q2 		$1.26M Sell
267,421
-132,819
-33% -$504K ﹤0.01% 2040
2018
Q1 		$1.27M Buy
400,240
+67,726
+20% +$273K ﹤0.01% 1969
2017
Q4 		$1.63M Buy
332,514
+88,725
+36% +$515K ﹤0.01% 1818
2017
Q3 		$1.67M Sell
243,789
-79,217
-25% -$499K ﹤0.01% 1760
2017
Q2 		$2.13M Sell
323,006
-178,500
-36% -$1.25M ﹤0.01% 1535
2017
Q1 		$4.01M Buy
501,506
+20,159
+4% +$170K 0.01% 1130
2016
Q4 		$4.48M Buy
481,347
+45,452
+10% +$470K 0.01% 1054
2016
Q3 		$4.62M Buy
435,895
+33,246
+8% +$331K 0.01% 989
2016
Q2 		$3.76M Buy
402,649
+74,124
+23% +$753K 0.01% 1002
2016
Q1 		$3.41M Buy
328,525
+67,933
+26% +$621K 0.01% 1010
2015
Q4 		$2.62M Sell
260,592
-4,251
-2% -$42.6K 0.01% 1120
2015
Q3 		$2.23M Buy
264,843
+94,974
+56% +$1.26M 0.01% 1149
2015
Q2 		$2.73M Buy
169,869
+9,354
+6% +$145K 0.01% 1151
2015
Q1 		$2.27M Sell
160,515
-52,213
-25% -$679K 0.01% 1168
2014
Q4 		$2.13M Sell
212,728
-48,534
-19% -$415K 0.01% 1121
2014
Q3 		$2.22M Buy
261,262
+14,374
+6% +$126K 0.01% 1049
2014
Q2 		$2.18M Buy
246,888
+25,222
+11% +$220K 0.01% 1043
2014
Q1 		$2.07M Buy
221,666
+7,131
+3% +$62.5K 0.01% 1023
2013
Q4 		$1.81M Buy
214,535
+124,448
+138% +$1.26M 0.01% 1020
2013
Q3 		$794K Buy
90,087
+46,622
+107% +$374K 0.01% 1372
2013
Q2 		$309K Buy
+43,465
New +$300K ﹤0.01% 1708

Other funds holding OPK

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James & Associates's OPK Position: Q3 2024 in Review

Raymond James & Associates increased its Opko Health (OPK) stake by 1% in Q3 2024, buying an estimated $594 and bringing the position to 38,665 shares worth $57.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3837.

Raymond James & Associates first reported a position in OPK in Q2 2013 and has held it in 46 quarters since. The position peaked at $4.62M in Q3 2016. 234 funds tracked by Wall St. Rank hold OPK as of Q3 2024.

  • Raymond James & Associates held 38,665 shares of Opko Health worth $57.6K as of Q3 2024.
  • Raymond James & Associates bought 400 Opko Health shares in Q3 2024, an estimated $594.
  • Opko Health made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3837 holding.
  • Raymond James & Associates first reported a position in Opko Health in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Opko Health position peaked at $4.62M in Q3 2016.
  • 234 funds tracked by Wall St. Rank held Opko Health as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.